Actinium (ATNM) Director C. David Nicholson Receives RSU and Derivative Awards

What Happened

• C. David Nicholson, a director of Actinium Pharmaceuticals (ATNM), was granted a total of 157,000 equity awards on 2026-09-02: 62,800 restricted stock units (RSUs) and 94,200 derivative awards. Both grants show an acquisition price of $0.00, meaning they were awarded as compensation rather than purchased for cash.

Key Details

• Transaction date: 2026-09-02; Form 4 filed 2026-09-04 (filed within the typical two-business-day window).
• Award amounts and prices: 62,800 RSUs @ $0.00; 94,200 derivative awards @ $0.00 (total 157,000 awards).
• Shares owned after the transaction: not disclosed in the filing.
• Vesting/other notes:
  • F1: The 62,800 RSUs vest 1/3 on each anniversary for three years.
  • F2: The 94,200 derivative awards (stock options) vest in 50 equal monthly tranches beginning on the grant date.
• No indication the awards were immediately sellable; these are compensation grants, not open-market purchases or sales.

Context

• RSUs and unexercised options generally are not immediately tradable; they vest over time and may dilute shares if exercised/settled. Awards are a routine form of executive/director compensation and do not by themselves indicate the insider is buying or selling stock for portfolio reasons.